MXPA99010840A - Compositions containing select liquid polyol fatty acid polyesters - Google Patents
Compositions containing select liquid polyol fatty acid polyestersInfo
- Publication number
- MXPA99010840A MXPA99010840A MXPA/A/1999/010840A MX9910840A MXPA99010840A MX PA99010840 A MXPA99010840 A MX PA99010840A MX 9910840 A MX9910840 A MX 9910840A MX PA99010840 A MXPA99010840 A MX PA99010840A
- Authority
- MX
- Mexico
- Prior art keywords
- fatty acid
- polyol
- polyester
- composition
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 154
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 96
- 239000000194 fatty acid Substances 0.000 title claims abstract description 96
- -1 polyol fatty acid Chemical class 0.000 title claims abstract description 69
- 229920005862 polyol Polymers 0.000 title claims abstract description 67
- 229920000728 polyester Polymers 0.000 title claims abstract description 63
- 239000007788 liquid Substances 0.000 title claims abstract description 39
- 150000004665 fatty acids Chemical group 0.000 claims abstract description 58
- 150000003077 polyols Chemical group 0.000 claims abstract description 42
- 210000003491 Skin Anatomy 0.000 claims abstract description 41
- 239000007787 solid Substances 0.000 claims abstract description 40
- 230000000699 topical Effects 0.000 claims abstract description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 31
- 238000002844 melting Methods 0.000 claims abstract description 23
- 125000004432 carbon atoms Chemical group C* 0.000 claims abstract description 14
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims description 43
- 239000005720 sucrose Substances 0.000 claims description 43
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 42
- 229960004793 Sucrose Drugs 0.000 claims description 42
- 239000003921 oil Substances 0.000 claims description 38
- 235000019198 oils Nutrition 0.000 claims description 38
- 239000000516 sunscreening agent Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 10
- 239000006210 lotion Substances 0.000 claims description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000000600 sorbitol Substances 0.000 claims description 9
- 235000010356 sorbitol Nutrition 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 229960001031 Glucose Drugs 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 239000004909 Moisturizer Substances 0.000 claims description 7
- 239000004264 Petrolatum Substances 0.000 claims description 7
- 229940066842 Petrolatum Drugs 0.000 claims description 7
- 150000002191 fatty alcohols Chemical class 0.000 claims description 7
- 150000002430 hydrocarbons Chemical class 0.000 claims description 7
- 230000001333 moisturizer Effects 0.000 claims description 7
- 235000019271 petrolatum Nutrition 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- 230000003255 anti-acne Effects 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 230000000475 sunscreen Effects 0.000 claims description 6
- 230000001815 facial Effects 0.000 claims description 5
- 235000013772 propylene glycol Nutrition 0.000 claims description 5
- 239000004135 Bone phosphate Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 Xylitol Drugs 0.000 claims description 4
- 230000003750 conditioning Effects 0.000 claims description 4
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 4
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- 229940009714 Erythritol Drugs 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 238000005562 fading Methods 0.000 claims description 2
- 238000005187 foaming Methods 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 229920005906 polyester polyol Polymers 0.000 claims description 2
- 230000001012 protector Effects 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 239000007934 lip balm Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 description 23
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 13
- 239000003549 soybean oil Substances 0.000 description 13
- 235000012424 soybean oil Nutrition 0.000 description 13
- 239000002537 cosmetic Substances 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 11
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000003995 emulsifying agent Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940079593 drugs Drugs 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- 229920001888 polyacrylic acid Polymers 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- DUFKCOQISQKSAV-UHFFFAOYSA-N 2-(2-hydroxypropoxy)propan-1-ol Chemical compound CC(O)COC(C)CO DUFKCOQISQKSAV-UHFFFAOYSA-N 0.000 description 8
- 239000003974 emollient agent Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- UQEAIHBTYFGYIE-UHFFFAOYSA-N Hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 5
- 125000005250 alkyl acrylate group Chemical group 0.000 description 5
- 230000000845 anti-microbial Effects 0.000 description 5
- 229940008099 dimethicone Drugs 0.000 description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 description 5
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 5
- 235000020778 linoleic acid Nutrition 0.000 description 5
- 239000004973 liquid crystal related substance Substances 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 5
- 235000021313 oleic acid Nutrition 0.000 description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 5
- 229960001631 Carbomer Drugs 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 229960003487 Xylose Drugs 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 150000001479 arabinose derivatives Chemical class 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 229920001223 polyethylene glycol Chemical class 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 3
- WXZMFSXDPGVJKK-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 3
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 3
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 3
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 3
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 3
- 229960000448 Lactic acid Drugs 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N Phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- 229960005323 Phenoxyethanol Drugs 0.000 description 3
- 239000002202 Polyethylene glycol Chemical class 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 150000001253 acrylic acids Chemical class 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 230000000111 anti-oxidant Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000003212 astringent agent Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 229960003500 triclosan Drugs 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 2
- FKMHSNTVILORFA-UHFFFAOYSA-N 2-[2-(2-dodecoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCO FKMHSNTVILORFA-UHFFFAOYSA-N 0.000 description 2
- HSEXOZXVUZVSDZ-UHFFFAOYSA-N 2-[2-ethylhexyl(methyl)amino]benzoic acid Chemical compound CCCCC(CC)CN(C)C1=CC=CC=C1C(O)=O HSEXOZXVUZVSDZ-UHFFFAOYSA-N 0.000 description 2
- WJLVQTJZDCGNJN-UHFFFAOYSA-N 2-[6-[[amino-[[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;hydron;dichloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- 229940090958 BEHENYL BEHENATE Drugs 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- 241000273930 Brevoortia tyrannus Species 0.000 description 2
- JNIIDKODPGHQSS-DHDCSXOGSA-N Capreomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)C(CNC(=O)CC(N)CCCN)NC(=O)C(CO)NC(=O)C(N)CNC(=O)C1C1NC(N)=NCC1 JNIIDKODPGHQSS-DHDCSXOGSA-N 0.000 description 2
- 108010065839 Capreomycin Proteins 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229960004504 Chlorhexidine Hydrochloride Drugs 0.000 description 2
- 229960004475 Chlortetracycline Drugs 0.000 description 2
- 239000004099 Chlortetracycline Substances 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 229960003722 Doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N Erucic acid Chemical class CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 2
- YTBSYETUWUMLBZ-IUYQGCFVSA-N Erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 2
- 206010056474 Erythrosis Diseases 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N Eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N Kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229940057905 Laureth-3 Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N Lauric acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 210000000088 Lip Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl methoxycinnamate Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- 229940100460 PEG-100 Stearate Drugs 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N Pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- 229960004448 Pentamidine Drugs 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N Piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- 229920001451 Polypropylene glycol Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 2
- 229960002180 Tetracycline Drugs 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 2
- 229960001727 Tretinoin Drugs 0.000 description 2
- 229940046282 Zinc Drugs 0.000 description 2
- 229940091251 Zinc Supplements Drugs 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 230000000202 analgesic Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 229960003328 benzoyl peroxide Drugs 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 235000019365 chlortetracycline Nutrition 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Chemical class O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- NJIMZDGGLTUCPX-UHFFFAOYSA-N docosyl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCCCCCC NJIMZDGGLTUCPX-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229960004275 glycolic acid Drugs 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 230000003370 grooming Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000011874 heated mixture Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- BJHIKXHVCXFQLS-PYWDMBMJSA-N keto-D-sorbose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PYWDMBMJSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical class OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229950001046 piroctone Drugs 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229960001755 resorcinol Drugs 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960005349 sulfur Drugs 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N (1S,3R,4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,25R,27R,29R,32R,33R,35S,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- FIWSRSRCWYARAJ-SQOFCNSWSA-N (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol;(Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FIWSRSRCWYARAJ-SQOFCNSWSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- AUODDLQVRAJAJM-XJQDNNTCSA-N (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 AUODDLQVRAJAJM-XJQDNNTCSA-N 0.000 description 1
- OIQXFRANQVWXJF-QBFSEMIESA-N (2Z)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound CC1(C)C2CCC1(C)C(=O)\C2=C/C1=CC=CC=C1 OIQXFRANQVWXJF-QBFSEMIESA-N 0.000 description 1
- VXPSARQTYDZXAO-CCHMMTNSSA-N (4S,4aR,5S,5aR,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O VXPSARQTYDZXAO-CCHMMTNSSA-N 0.000 description 1
- SVDOODSCHVSYEK-IFLJXUKPSA-N (4S,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O SVDOODSCHVSYEK-IFLJXUKPSA-N 0.000 description 1
- YCIHPQHVWDULOY-FMZCEJRJSA-N (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O YCIHPQHVWDULOY-FMZCEJRJSA-N 0.000 description 1
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- OIJAYOZHXTXUBD-TXDFQOQUSA-N (Z)-octadec-9-enoic acid;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCC\C=C/CCCCCCCC(O)=O OIJAYOZHXTXUBD-TXDFQOQUSA-N 0.000 description 1
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N 1-Tetradecanol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 description 1
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 1
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- QWBBPBRQALCEIZ-UHFFFAOYSA-N 2,3-Dimethylphenol Chemical compound CC1=CC=CC(O)=C1C QWBBPBRQALCEIZ-UHFFFAOYSA-N 0.000 description 1
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 1
- WVCHIGAIXREVNS-UHFFFAOYSA-N 2-HYDROXY-1,4-NAPHTHOQUINONE Chemical compound C1=CC=C2C(O)=CC(=O)C(=O)C2=C1 WVCHIGAIXREVNS-UHFFFAOYSA-N 0.000 description 1
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-Methyl-2,4-pentanediol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- ZQBJRVYLUFBBEQ-UHFFFAOYSA-N 2-[diamino(3-formamidopropyl)azaniumyl]acetate Chemical compound [O-]C(=O)C[N+](N)(N)CCCNC=O ZQBJRVYLUFBBEQ-UHFFFAOYSA-N 0.000 description 1
- IKVCSHRLYCDSFD-UHFFFAOYSA-N 2-hexadecanoyloxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCC IKVCSHRLYCDSFD-UHFFFAOYSA-N 0.000 description 1
- YDZIJQXINJLRLL-UHFFFAOYSA-N 2-hydroxylauric acid Chemical compound CCCCCCCCCCC(O)C(O)=O YDZIJQXINJLRLL-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methylpentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N 2-phenyl-3H-benzimidazole-5-sulfonic acid Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- ILYSAKHOYBPSPC-UHFFFAOYSA-N 2-phenylbenzoic acid Chemical class OC(=O)C1=CC=CC=C1C1=CC=CC=C1 ILYSAKHOYBPSPC-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical group C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-Aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- HEOCBCNFKCOKBX-SDNWHVSQSA-N 4-Methylbenzylidene camphor Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)C2(C)CCC\1C2(C)C HEOCBCNFKCOKBX-SDNWHVSQSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UMZBRFQRSA-N 4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CCC1(C)C1C2C2CCC(C(CCC(O)=O)C)C2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UMZBRFQRSA-N 0.000 description 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
- BDQHDFBEAFMWII-UHFFFAOYSA-N 6-hydroxyhexanal;hydrochloride Chemical compound Cl.OCCCCCC=O BDQHDFBEAFMWII-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 1
- 229940063953 AMMONIUM LAURYL SULFATE Drugs 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 229940031012 ANTI-ACNE PREPARATIONS Drugs 0.000 description 1
- 229940022659 Acetaminophen Drugs 0.000 description 1
- 229940091181 Aconitic Acid Drugs 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N Aconitic acid Chemical compound OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Alimemazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N Alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960001656 Amikacin Sulfate Drugs 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N Ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- PQUCIEFHOVEZAU-UHFFFAOYSA-N Ammonium sulfite Chemical compound [NH4+].[NH4+].[O-]S([O-])=O PQUCIEFHOVEZAU-UHFFFAOYSA-N 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Azelaic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 229940093761 Bile Salts Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N Bupivacaine Chemical class CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 229940048851 CETYL RICINOLEATE Drugs 0.000 description 1
- GGQJXCQBBONZFX-IWVLMIASSA-N CHEMBL1237124 Chemical compound C=C([C@H]1[C@@H]2O)C3=C(Cl)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O GGQJXCQBBONZFX-IWVLMIASSA-N 0.000 description 1
- VGJYLQBMVKVTBK-UHFFFAOYSA-N C[N-]CCCCCCCCCC Chemical compound C[N-]CCCCCCCCCC VGJYLQBMVKVTBK-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical class C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 229960000846 Camphor Drugs 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N Carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003260 Chlorhexidine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N Cinchocaine Chemical class C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 229960001200 Clindamycin Hydrochloride Drugs 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229940031766 DIETHANOLAMINE CETYL PHOSPHATE Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 229940009976 Deoxycholate Drugs 0.000 description 1
- 229940120099 Dibucaine Drugs 0.000 description 1
- 229940120503 Dihydroxyacetone Drugs 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N Dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 229940101029 Dipotassium Glycyrrhizinate Drugs 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N Dodecanol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229960003203 Erythromycin Estolate Drugs 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N Ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- 229960000285 Ethambutol Drugs 0.000 description 1
- 229960001618 Ethambutol Hydrochloride Drugs 0.000 description 1
- 229960003976 Etidocaine Drugs 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical class CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 229940044949 Eucalyptus oil Drugs 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 229960002217 Eugenol Drugs 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N Fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229950001284 Fluprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N Glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N Hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- UXNFIJPHRQEWRQ-UHFFFAOYSA-N Hexamethylenetetramine mandelate salt Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)C(O)C1=CC=CC=C1 UXNFIJPHRQEWRQ-UHFFFAOYSA-N 0.000 description 1
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical class C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N Homosalate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- 229960004881 Homosalate Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- RJMIEHBSYVWVIN-UHFFFAOYSA-N Indoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N Isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N Itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960002064 Kanamycin Sulfate Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- OYHQOLUKZRVURQ-UHFFFAOYSA-N Linoleic acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- MHIGBKBJSQVXNH-IWVLMIASSA-N Metacycline Chemical compound C=C([C@H]1[C@@H]2O)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O MHIGBKBJSQVXNH-IWVLMIASSA-N 0.000 description 1
- 229940042016 Methacycline Drugs 0.000 description 1
- 229960004011 Methenamine Drugs 0.000 description 1
- 229960000282 Metronidazole Drugs 0.000 description 1
- 229960002395 Metronidazole Hydrochloride Drugs 0.000 description 1
- 229940042472 Mineral Oil Drugs 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960002421 Minocycline Hydrochloride Drugs 0.000 description 1
- OJGQFYYLKNCIJD-UHFFFAOYSA-N Miroprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 OJGQFYYLKNCIJD-UHFFFAOYSA-N 0.000 description 1
- 229950006616 Miroprofen Drugs 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- QAUSZAVWASXGEA-UHFFFAOYSA-N N-(2-amino-1-hydroxyethyl)acetamide Chemical compound CC(=O)NC(O)CN QAUSZAVWASXGEA-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-M N-benzoylglycinate Chemical compound [O-]C(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-M 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N Neomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 229940053050 Neomycin Sulfate Drugs 0.000 description 1
- 229960000808 Netilmicin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N Norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 Norfloxacin Drugs 0.000 description 1
- OVVINEZSSVQLTB-NRQGAZJASA-N OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O OVVINEZSSVQLTB-NRQGAZJASA-N 0.000 description 1
- FIZKODOSXKHWJZ-NBHOPJAXSA-N OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O FIZKODOSXKHWJZ-NBHOPJAXSA-N 0.000 description 1
- SKLXVOYUKZEQHP-FHUUETBYSA-N OC[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O SKLXVOYUKZEQHP-FHUUETBYSA-N 0.000 description 1
- WRZWDZPRYBQFQX-YIKGDQNVSA-N OC[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/CCCCCCCC(O)=O WRZWDZPRYBQFQX-YIKGDQNVSA-N 0.000 description 1
- 229960003921 Octisalate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N Octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N Oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960000625 Oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229960004368 Oxytetracycline Hydrochloride Drugs 0.000 description 1
- 229940051841 POLYOXYETHYLENE ETHER Drugs 0.000 description 1
- 229940115476 PPG-1 TRIDECETH-6 Drugs 0.000 description 1
- 229940078492 PPG-17 Drugs 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 229960005065 Paromomycin Sulfate Drugs 0.000 description 1
- TXFPEBPIARQUIG-UHFFFAOYSA-N Piceol Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N Pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940068977 Polysorbate 20 Drugs 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N Pramocaine Chemical class C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- KQTIIICEAUMSDG-UHFFFAOYSA-N Propane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 229940040608 SPS Drugs 0.000 description 1
- 229940098760 STEARETH-2 Drugs 0.000 description 1
- 229940100459 STEARETH-20 Drugs 0.000 description 1
- 229940100458 STEARETH-21 Drugs 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 229950011392 Sorbitan stearate Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N Squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ABTZKZVAJTXGNN-UHFFFAOYSA-N Stearyl heptanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCC ABTZKZVAJTXGNN-UHFFFAOYSA-N 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 229960002385 Streptomycin Sulfate Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 229960004492 Suprofen Drugs 0.000 description 1
- MDKGKXOCJGEUJW-UHFFFAOYSA-N Suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 description 1
- 229960002372 Tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical class CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960000707 Tobramycin Drugs 0.000 description 1
- 229960004477 Tobramycin Sulfate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N Tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229940035740 Trimeprazine Drugs 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229940045997 Vitamin A Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 229940118846 Witch Hazel Drugs 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical class CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- OCRUMFQGIMSFJR-FSAWCSQFSA-N [(2S,3S,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-[(Z)-octadec-9-enoyl]oxy-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl (Z)-octadec-9-enoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC OCRUMFQGIMSFJR-FSAWCSQFSA-N 0.000 description 1
- VFCBYFDYBODXCH-YGWGHPONSA-N [(2S,3S,4R,5R)-5-(hydroxymethyl)-3,4-bis[[(Z)-octadec-9-enoyl]oxy]-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl (Z)-octadec-9-enoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC VFCBYFDYBODXCH-YGWGHPONSA-N 0.000 description 1
- ZZXIXQRNGZFIQT-JSJITEFISA-N [(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl (Z)-octadec-9-enoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O ZZXIXQRNGZFIQT-JSJITEFISA-N 0.000 description 1
- HVUMOYIDDBPOLL-IIZJTUPISA-N [2-[(2R,3S,4R)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@@H](O)[C@@H]1O HVUMOYIDDBPOLL-IIZJTUPISA-N 0.000 description 1
- SCMSRHIBVBIECI-UHFFFAOYSA-N [2-hydroxy-4-(2-hydroxyethoxy)phenyl]-phenylmethanone Chemical compound OC1=CC(OCCO)=CC=C1C(=O)C1=CC=CC=C1 SCMSRHIBVBIECI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- FXKSEJFHKVNEFI-GCZBSULCSA-N amikacin disulfate Chemical compound [H+].[H+].[H+].[H+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O FXKSEJFHKVNEFI-GCZBSULCSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging Effects 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000842 anti-protozoal Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 230000001153 anti-wrinkle Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic products Propionic acid derivatives Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 239000010480 babassu oil Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- 229930000006 bisabolols Natural products 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 229930007890 camphor Natural products 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000001470 diamides Chemical class 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- HOWGUJZVBDQJKV-UHFFFAOYSA-N docosane Chemical compound CCCCCCCCCCCCCCCCCCCCCC HOWGUJZVBDQJKV-UHFFFAOYSA-N 0.000 description 1
- 229950008690 docosanoic acid Drugs 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 1
- 229950001028 erythromycin propionate Drugs 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical class OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- XAMHKORMKJIEFW-AYTKPMRMSA-N hexadecyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC XAMHKORMKJIEFW-AYTKPMRMSA-N 0.000 description 1
- GKKMCECQQIKAHA-UHFFFAOYSA-N hexadecyl dihydrogen phosphate;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.CCCCCCCCCCCCCCCCOP(O)(O)=O GKKMCECQQIKAHA-UHFFFAOYSA-N 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-L hexadecyl phosphate Chemical compound CCCCCCCCCCCCCCCCOP([O-])([O-])=O ZUVCYFMOHFTGDM-UHFFFAOYSA-L 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- YDLYQMBWCWFRAI-UHFFFAOYSA-N hexatriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC YDLYQMBWCWFRAI-UHFFFAOYSA-N 0.000 description 1
- 229960005388 hexylcaine Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
- 239000010512 hydrogenated peanut oil Substances 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 229910000460 iron oxide Inorganic materials 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 230000001530 keratinolytic Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000010699 lard oil Substances 0.000 description 1
- 229950004594 levomenol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 229960000826 meclocycline Drugs 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical class CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960003494 metacycline Drugs 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 229960002786 methenamine mandelate Drugs 0.000 description 1
- LPEKGGXMPWTOCB-UHFFFAOYSA-N methyl 2-hydroxypropionate Chemical compound COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229940057867 methyl lactate Drugs 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical compound Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
- GLMUAFMGXXHGLU-VQAITOIOSA-N minocycline hydrochloride Chemical compound [H+].[Cl-].C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O GLMUAFMGXXHGLU-VQAITOIOSA-N 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000003020 moisturizing Effects 0.000 description 1
- 235000019508 mustard seed Nutrition 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- GAQPWOABOQGPKA-UHFFFAOYSA-N octadecyl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCC GAQPWOABOQGPKA-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- VNLRTFSQCPNNIM-UHFFFAOYSA-N octadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC VNLRTFSQCPNNIM-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000003711 photoprotective Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002553 poly(2-methacrylolyloxyethyltrimethylammonium chloride) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- AMCPECLBZPXAPB-UHFFFAOYSA-N propane-1,2,3-triol;sodium Chemical compound [Na].OCC(O)CO AMCPECLBZPXAPB-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2(1H)-one Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 231100000051 skin sensitiser Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940098758 stearyl heptanoate Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UYERRXOXXRNFHC-UHFFFAOYSA-N tridodecyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCCCCCC)CC(=O)OCCCCCCCCCCCC UYERRXOXXRNFHC-UHFFFAOYSA-N 0.000 description 1
- 229940118576 triisostearyl citrate Drugs 0.000 description 1
- ICWQKCGSIHTZNI-UHFFFAOYSA-N tris(16-methylheptadecyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCCCCCCCCCC(C)C)CC(=O)OCCCCCCCCCCCCCCCC(C)C ICWQKCGSIHTZNI-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
Abstract
Disclosed are compositions suitable for topical application to human hair or skin, which comprise a combination of a liquid polyol fatty acid polyester having a melting point of from about -30°C to about 30°C, and a solid oil other than a solid polyol fatty acid polyester having a melting point of above about 30°C to about 250°C, wherein said liquid polyol fatty acid polyester has a polyol moiety and at least 1 fatty acid moiety, the polyol moiety having at least 4 free hydroxyl groups wherein at least 60%of these free hydroxyl groups are esterified with one or more fatty acid moieties having from about 8 to about 22 carbon atoms. The composition preferably further comprises a topical carrier for the liquid polyol fatty acid polyester and solid oil combination. The composition provides effective emolliency and aesthetic benefits.
Description
COMPOSITIONS CONTAINING SELECTIVE POLYOLIC FLUID ACID LIQUID POLYESTERS
TECHNICAL FIELD
The present invention relates to compositions suitable for topical application to hair or human skin, which comprise a select combination of polyol fatty acid polyesters having a melting point between -30 ° C and 30 ° C and solid oils which They have a melting point above 30 ° C.
BACKGROUND OF THE INVENTION
For many years, topical compositions containing emollients have been used for the treatment of human hair or skin. For example, occlusive hydrocarbons, such as petrolatum, have been used as topical emollients to provide a protective film on human skin to prevent the loss of water into the environment. Petrolatum has also been used in hair care products such as conditioners and grooming aids. However, the most effective and most widely used compositions contain occlusive emollients that exhibit negative aesthetic qualities such as tackiness and greasiness.
In addition, some occlusive emollients that are used to provide a protective film on the skin result in the clogging of the pores of the skin and prevent the flow of oxygen. This obstruction of the surface of the skin or blocking of the passageway or of the circulation of air and moisture limits the use of such heavy occlusive emollient materials. Additionally, European Patent No. 458, 600 B1, published on March 2, 1994, discloses skin care occlusive compositions containing a polyol fatty acid polyester having at least 4 free hydroxyl groups, of which at least 60% are esterified with one or more fatty acids having 8 to 22 carbon atoms which can form an occlusive film on the skin after topical application thereon. U.S. Patent No. 5,160, 738, to Macaulay et al., Issued November 3, 1992, further discloses occlusive compositions containing a combination of two or more polyol fatty acid polyesters which have the appearance and physical properties of petrolatum. However, these compositions also have the disadvantage of being heavy and can clog the pores of the skin by preventing the flow of oxygen. It has now been discovered that compositions containing occlusive emollients can be formulated without being heavy, sticky or greasy. These compositions contain a select combination of polyol fatty acid polyesters having a melting point of -30 ° C to about 30 ° C, and solid oils having a melting point above 30 ° C, and such compositions are They can be applied in a variety of products to provide both efficacy and aesthetic benefits. It is therefore an object of the present invention to provide a composition having effective emotion and acceptable aesthetic qualities, and which contains an occlusive emollient used in combination with a solid oil. It is also an object of the present invention to provide topical compositions containing polyol fatty acid polyesters which are not heavy, sticky or greasy, and which are effective in the treatment of human skin or hair.
BRIEF DESCRIPTION OF THE INVENTION
The present invention relates to a composition suitable for topical application to the human skin or hair, which comprises a polyol polyester fatty acid polyester having a melting point of -30 ° C to about 30 ° C, and a solid oil other than the solid polyol fatty acid polyester having a melting point above 30 ° C to about 250 ° C, wherein said liquid polyol fatty acid polyester has a polyol portion and at least a portion of fatty acid, the polyol portion having at least four free hydroxyl groups wherein at least 60% of these free hydroxyl groups are esterified with one or more fatty acid portions having from 8 to 22 carbon atoms.
The preferred composition further comprises a topical vehicle for the polyol polyester fatty acid polyester and the solid oil combination. All percentages and ratios used herein are by weight and all measurements made at 25 ° C, unless otherwise stated. The invention may comprise, consist of or consist essentially of, the essential as well as optional ingredients and components described herein.
DETAILED DESCRIPTION OF THE INVENTION
The term "topical composition" as used herein means a composition suitable for topical application to human skin or hair. The term is used to encompass a wide variety of compositions for personal care, beauty care and cosmetic. Non-limiting examples of topical compositions include lotions, creams, hand and body lotions, skin conditioning lotions and creams, skin protecting compositions, sun blocking compositions, fading creams, anti-acne compositions, products for the renewal of the skin, non-foaming cleansing lotions, moisturizers, facial moisturizers, makeup, foundation, lipstick, lip protectors, skin cleansers, hand cleaners, face and body, shower products, shampoos and the like.
The term "topical vehicle", as used herein, is well known to those skilled in the art and means one or more diluents or liquid or solid filler vehicles that are suitable for administration to a human. The term "compatible", as used herein, means that the components of the topical vehicle can be mixed with the components of the present invention and with each other, in such a way that there is no interaction that can substantially reduce the effectiveness or aesthetics of the cosmetic composition under ordinary situations of use. The topical vehicle must be a pharmaceutically acceptable vehicle. The term "pharmaceutically acceptable" as used herein, means that the topical carrier must be of a sufficiently high purity and must be suitable for use when placed in contact with human skin or hair without undue toxicity, incompatibility, instability, allergic response and the like. The melting point of the polyol fatty acid polyesters and solid oils can be determined using conventional techniques. Such techniques are well defined in the art, and include thermometric as well as calorimetric methodology. A particularly preferred technique for determining the melting point is described in the patent E.U.A. No.5, 306,514 for Letton et al., Issued April 26, 1994, which is hereby incorporated by reference in its entirety. This technique typically involves the measurement of melting points using differential scanning calorimetry (DSC) where a sweep temperature of 5 ° C / minute is used to measure the melting point. The melting point is the temperature at the intersection of the baseline, that is, the specific heat line, with the line tangent to the trailing edge of the endothermic peak.
Polyethylene liquid polyol fatty acid The composition of the present invention consists of a polyol polyester fatty acid polyester in concentrations ranging from 0.1% to 99.9%, preferably from 0.5% to 75%, most preferred from 1% to 50%, even more preferred from 2% to 25% by weight of the composition. These liquid polyol fatty acid polyesters have melting points below 30 ° C, and are obtained from any aliphatic or aromatic polyol having at least 4 free hydroxyl groups, of which at least 60% of these Free hydroxyl groups are then esterified with one or more fatty acids having from 8 to 22 carbon atoms. Fatty acids can also be described as carboxylic acids, because the terms fatty acid and carboxylic acid are frequently used interchangeably by those skilled in the art. The liquid polyol polyesters used in this invention consist of certain polyols, especially sugar alcohols or sugars, esterified with one or more fatty acid groups. Accordingly, the polyol starting material must have at least 4 esterifiable hydroxyl groups. Examples of preferred polyols are sugars, including monosaccharides and disaccharides and sugar alcohols. Examples of monosaccharides containing four hydroxyl groups are xylose and arabinose and the sugar alcohol obtained from xylose, which has five hydroxyl groups, ie xylitol. The monosaccharide, erythrose, is not suitable in the practice of this invention, since it only contains three hydroxyl groups, but the sugar alcohol obtained from erythrose, ie erythritol, contains four hydroxyl groups and can therefore be used. Monosaccharides containing five appropriate hydroxyl groups are galactose, fructose and sorbose. Sugar alcohols containing 6 hydroxyl groups obtained from the hydrolysis products of sucrose, as well as glucose and sorbose, for example sorbitol, are also suitable. Examples of polyols and saccharides that can be used include maltose, lactose and sucrose, of which all contain eight hydroxyl groups. The polyols used in the polyol liquid esters of the present invention have from 4 to about 12, preferably from 4 to 11, and more preferred from about 4 to 8 hydroxyl groups. The preferred polyols for preparing the polyesters that are used in the present invention are selected from the group consisting of erythritol, xylitol, sorbitol, glucose and sucrose. Sucrose is especially preferred. The preferred polyol starting material having at least four hydroxyl groups must be esterified in at least 60% of the hydroxyl groups with a fatty acid containing from 8 to 22 carbon atoms, preferably from 8 to 18 carbon atoms. . Examples of such fatty acids include caprylic, capric, lauric, myristic, myristoleic, palmitic, palmitoleic, stearic, oleic, ricinoleic, linoleic, linolenic, eleostearic, arachidic, arachidonic, behenic and erucic acids. Fatty acids can be obtained from fatty acids that occur in nature or from synthetic fatty acids; these can be saturated or unsaturated, including positional and geometric isomers. However, to properly provide liquid polyesters of the type used herein, at least about half the fatty acid incorporated in the polyester molecule must be unsaturated. Oleic and linoleic acids and mixtures thereof are especially preferred. The liquid polyol fatty acid polyesters useful in this invention must contain one or more fatty acid ester groups. It is not necessary that all of the hydroxyl groups of the polyol be esterified with fatty acids, but it is preferable that at least 60% of the hydroxyl groups are esterified with fatty acid ester groups. Preferably, substantially all of the hydroxyl groups of the polyol are esterified with fatty acids, ie the polyol portion is completely esterified. The fatty acids esterified to the polyol molecule can be the same or mixed, but as indicated above, a substantial amount of the unsaturated acid ester groups must be present to provide liquid character. To illustrate the above points, a fatty acid di-ester of sucrose would be suitable for use herein, but is not preferred because it has more than two non-esterified hydroxyl groups. Similarly, a sucrose fatty acid tetra ester would be appropriate, but it is not preferred because it also has more than two non-esterified hydroxyl groups. Highly preferred compounds in which all hydroxyl groups are esterified with fatty acids include liquid sucrose-substituted octa-ester fatty acids. The following are non-limiting examples of polyol fatty acid polyesters containing one or more fatty acid ester groups suitable for use in the present invention: glucose oleate, glucose ester of the fatty acids (unsaturated) of soybean oil, fatty acid ester of mixed soybean oil, galactose ester of oleic acid, arabinose ester of linoleic acid, xylose linoleate, sorbitol oleate, sucrose oleate, glucose dioleate, glucose diesters of fatty acids (unsaturated) of soybean oil, digesters of the fatty acids of the mixed soybean oil, galactose diesters of oleic acid, arabinose diesters of linoleic acid, xylose dilinoleate, sorbitol dioleate, sucrose dioleate, glucose trioleate , glucose triesters of the fatty acids (unsaturated) of the soybean oil, triesters of the fatty acids of the soybean oil mixed, galactose triesters of oleic acid, arabinose triesters of linoleic acid, xylose trilinoleate, sorbitol trioleate, sucrose trioleate, glucose tetraesters of the fatty acids (unsaturated) of soybean oil, sugar cane tetraesters Fatty acids of mixed soybean oil, galactose tetraesters of oleic acid, tetraesters of arabinose of linoleic acid, tetralinoleate of xylose, tetraoleate of sorbitol, pentaoleate of galactose, hexaesters of sorbitol of unsaturated fatty acids of soybean oil, xylitol pentaoleate, sucrose tetraoleate, sucrose pentaoleate, sucrose hexaoleate, sucrose heptaoleate, sucrose octaoleate and mixtures thereof. Preferred are polyol liquid esters which are selected from the group consisting of sucrose pentaoleate, sucrose hexaoleate, sucrose heptaoleate, sucrose octaoleate and mixtures thereof. Most preferred are sucrose hexaoleate, sucrose heptaoleate, sucrose octaoleate and mixtures thereof. Preferred polyol fatty acid polyester polyols of the present invention have melting points between -30 ° C and 30 ° C, preferably from -30 ° C to about 27.5 ° C and more preferred from -30 ° C to 25 ° C . The melting points are measured using conventional techniques. The polyol fatty acid polyesters suitable for use herein can be prepared by a variety of methods well known to those skilled in the art. These methods include: transesterification of the polyol with methyl esters, ethyl or glycerol fatty acids used a variety of catalysts; acylation of the polyol with a fatty acid chloride; acylation of the polyol with a fatty acid anhydride; and acylating the polyol with a fatty acid per se. See patents E.U.A. No. 2,831, 854; patent E.U.A. No. 4,005,196, for Jandacek, issued January 25, 1977 and patent E.U.A. No. 4,005,196, for Jandacek, issued January 25, 1977, all of which are hereby incorporated herein by reference.
Solid oil The composition of the present invention comprises a solid oil which is used in combination with the polyol polyester fatty acid polyester described herein. The solid oil can be used as a single solid oil or a combination of solid oils, and are included in concentrations ranging from 0.1% to 99.9%, preferably from 0.5% to 75%, most preferred from 1% to 50%, even more preferred from 2% to 25% by weight of the composition. As used herein, the term "solid oils" refers to those materials that have a melting point above 30 ° C, preferably above 30 ° C to about 250 ° C, more preferred from 37 ° C at about 100 ° C, even more preferred from 37 ° C to about 80 ° C. Examples of suitable solid oils include, but are not limited to, petrolatum, highly branched hydrocarbons, fatty alcohols, fatty acid esters, vegetable oils, hydrogenated vegetable oils, propylene glycols, alpha-hydroxy fatty acids, fatty acids having from 10 to about 40 carbon atoms, alkylamides of di- and / or tribasic carboxylic acids, n-acylamino acid derivatives and mixtures thereof. The solid oils useful in the cosmetic composition of the present invention are described further in the patent E.U.A. No. 4,919,934, to Deckner et al., Issued April 24, 1990, which is hereby incorporated by reference in its entirety.
The highly branched hydrocarbons suitable for use herein include hydrocarbon compounds having from 17 to 40 carbon atoms. Non-limiting examples of these hydrocarbon compounds include squalane, cholesterol, lanolin, docosane (i.e. a C22 hydrocarbon) and isoparaffins. Fatty alcohols suitable for use herein include monohydric alcohols, ethoxylated fatty alcohols and fatty alcohol esters, excluding ethoxylated fatty alcohols and fatty alcohol esters useful as emulsifiers herein. Specific examples of commercially available fatty alcohols include, but are not limited to, Unilin 550, Unilin 700, Unilin 425, Unilin 400, Unilin 350 and Unilin 325, all supplied by Petrolite. Suitable ethoxylated fatty alcohols include, but are not limited to, Unithox 325, Unithox 400 and Unithox 450, Unithox 480, Unithox 520, Unithox 550, Unithox 720, Unithox 750, all of which can be obtained in Petrolite. Non-limiting examples of suitable fatty alcohol esters include tri-isostearyl citrate, ethylene glycol di-12-hydroxystearate, tristearyl citrate, stearyl octanoate, stearyl heptanoate and trilauryl citrate. Fatty acid esters suitable for use herein include ester waxes, monoglycerides, diglycerides, triglycerides and mixtures thereof. Non-limiting examples of suitable ester waxes include stearyl stearate, stearyl behenate, palmityl stearate, stearyloctyl decane, cetyl esters, cetearyl behenate, behenyl behenate, ethylene glycol distearate, ethylene glycol dipalmitate, and beeswax. Commercial examples of ester waxes include Kester waxes from Koster Keunen, Crodamol SS from Croda and Demalcare SPS from Rhone Poulenc. Vegetable oils and hydrogenated vegetable oils which are solid or semi-solid at ambient temperatures between 20 ° C and 25 ° C are also useful herein. Suitable examples of vegetable oils and hydrogenated vegetable oils include butter, chicken fat, goose fat, horse fat, lard oil (fatty tissue), rabbit fat, sardine oil, bait (beef), bait (from ram), Chinese vegetable bait, babassu oil, (Orbigynia speciosa or O. martiana), cocoa butter, coconut oil, palm oil, palm kernel oil, hydrogenated safflower oil, hydrogenated castor oil, hydrogenated coconut oil, hydrogenated cottonseed oil, hydrogenated menhaden oil (Brevoortia tyrannus), hydrogenated palm kernel oil, hydrogenated palm oil, hydrogenated peanut oil, hydrogenated soybean oil, oil of hydrogenated mustard seed, hydrogenated flaxseed oil, hydrogenated rice bran oil, hydrogenated sesame oil, hydrogenated sunflower seed oil, derivatives thereof and mixtures thereof. Propylene glycols suitable for use herein include alkyl (C -C-i6) propylene glycols esters and C1-C16 carboxylic acid esters of propylene glycols. Non-limiting examples of these materials include butyl ether of PPG-14, stearyl ether of PPG-15, PPG-9, PPG-12, PPG-15, PPG-17, PPG-20, PPG-26, PPG-30, PPG -34 and mixtures thereof. Examples of suitable alpha-hydroxy fatty acids and fatty acids having from 10 to 40 carbon atoms include 12-hydroxystearic acid, 2-hydroxylauric acid, 16-hydroxydecanoic acid, behenic acid, euric acid, stearic acid, caprylic acid, lauric acid , isostearic acid and mixtures thereof. Examples of some suitable fatty acids are described further in the patent E.U.A. 5,429,816, issued to Hofrichter et al., July 4, 1995; and the patent E.U.A. 5,552,136, issued to Motley on September 3, 1996, the descriptions of which are incorporated herein by reference. The alkylamides of di- and / or tribasic carboxylic acids suitable for use herein include disubstituted or branched monoamides, monosubstituted or branched diamides, triamides and mixtures thereof. Some specific examples of di- and tribasic carboxylic acid alkyl amides include, but are not limited to, citric acid alkylamides, tricarballylic acid, aconitic acid, nitrilotriacetic acid, and itaconic acid such as 1,2,3-propanedibutyl amide, 2-hydroxy -1, 2,3, -propantributylamide, 1-propen-1, 2,3-trioctylamide. N.N'N "-tri (methyldecylamide) amine, 2-docecyl-N.N'-dibutyl succinamide, and mixtures thereof Other suitable amides include the n-acylamino acid derivatives described in US Patent 5,429,816, issued to Hofrichter et al. on July 4, 1995.
Topical vehicle The composition of the present invention comprises from 0.1% to about 99.9%, preferably from 50% to 99% and more preferred from about 60% to 95% by weight of a topical vehicle for the combination of polyol polyester liquid polyester. fatty acid and solid oil, and for any of the other optional components of the present invention. The combination of polyol fatty acid polyester and solid oil of the present invention can be formulated into a wide variety of product types, including creams, lotions, liquid creams, gels, hand and body lotions, vanishing creams, cleansing lotions, foaming agents, facial moisturizers, sun blockers, anti-acne preparations, topical analgesics, make-up, lipstick, skin cleansers, hand cleaners, face and body, shower products, shampoo and the like. The vehicles and any additional components required to formulate such products will vary with the type of product and can be routinely chosen by one skilled in the art. The topical vehicle can be in a wide variety of forms. For example, emulsion vehicles, including but not limited to, oil / water, water / oil, water / oil / water, and water / oil / silicone emulsions, are useful herein. These emulsions can cover a wide range of viscosities, for example from 100 cps to about 2000 cps. Other suitable topical vehicles include anhydrous liquid solvents such as oils, alcohols and silicones (for example mineral oil, ethanol, isopropanol, dimethicone, cyclomethicone, and the like); single phase liquid solvents with aqueous base (for example hydroalcoholic solvent systems); and thickened versions of these anhydrous and single phase aqueous based solvents (for example, wherein the viscosity of the solvent has been increased to form a solid or semi-solid by the addition of appropriate gums, resin waxes, polymers, salts and Similar). Examples of topical carrier systems useful in the present invention are described in the following references of which all are incorporated herein by reference in their entirety: "Sun Products Formulary" Cosmetics & Toiletries, vol. 105, pp. 122-139 (December 1990); "Sun Products Formulary", Cosmetics & Toiletries. vol. 102, pp. 117-136 (March 1987); Patent E.U.A. No. 4,960,764 for Figueroa et al, issued October 2, 1990; Patent E.U.A. No. 4,254,105 to Fukuda et al, issued March 3, 1981; Patent E.U.A. No. 4,976,953, for Orr et al, issued December 11, 1990; U.S. Patent No. 5,073,372, to Turner et al, issued December 17, 1991; Patent E.U.A. No. 5,585,104, for Ha et al, issued December 17, 1996; Patent E.U.A. No. 5,607,678, for Moore et al, issued March 4, 1997; Patent E.U.A. No. 5,607,980, for McAtee et al, issued March 4, 1997; and Patent E.U.A. No. 5,618,522, to Kaleta et al, issued April 8, 1997. The topical vehicle may also comprise an oil-in-water emulsion system having complete structures such as liquid crystals and crystal gel networks. The nature of the liquid crystals, the formation of liquid crystals, the properties and advantages of the liquid crystals are further described in G. Dahms, Properties of O / W Emulsions With Anisotropic Lameliar Phases, 101 Cosmetics & Toiletries, 113-115 (1986); P. Loll, Liquid Crystals in Cosmetic Emulsions, ICI Surfactants' Publication RP94-93E and G. M. Eccleston, Multiple-Phase Oil-ln-Water Emulsions, 41, J. Soc. Cosmet. Chem, 1-22, (January / February 1990); of which all are incorporated herein for reference in their entirety.
Additional components A wide variety of additional components can be used in the compositions herein. Non-limiting examples include the following:
Active pharmaceutical ingredients The compositions of the present invention may comprise a safe and effective amount of a pharmaceutical active ingredient. The phrase "safe and effective amount", as used herein, means an amount of an active ingredient high enough to significantly or positively modify the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit ratio). / risk), within the field of well-founded medical judgment. A safe and effective amount of pharmaceutical active ingredient will vary with the specific active ingredient, the ability of the composition to penetrate the active ingredient through the skin, the amount of composition to be applied, the particular condition to be treated. , the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of the concurrent therapy and similar factors. The active pharmaceutical ingredients that can be used in the compositions of the present invention preferably constitute from 0.1% to 20% by weight of the compositions, more preferably from 0.1% to 10%, and more preferred from about 0.1% to about 5%. Mixtures of pharmaceutical active ingredients can also be used. Non-limiting examples of pharmaceutical active ingredients may include the following: Pharmaceutical active ingredients useful in the compositions of the present invention include anti-acne drugs. Anti-acne drugs which are used in the present invention include keratolytics such as salicylic acid, sulfur, lactic acid, glycolic acid, pyruvic acid, resorcinol and N-acetylcysteine; retinoids such as retinoic acid and its derivatives (for example cis and trans); antibiotics and antimicrobials such as benzoyl peroxide, octopirox, erythromycin, zinc, tetracycline, triclosan, azelaic acid and its derivatives, phenoxyethanol and phenoxypropanol, ethyl acetate, clindamycin and meclocycline; sebostáticos such as the flavinoides; alpha and beta hydroxy acids; and bile salts such as escimol sulfate and its derivatives, deoxycholate, and cholate. Preferred anti-acne active ingredients are those selected from the group consisting of salicylic acid, sulfur, resorcinol, lactic acid, zinc, erythromycin, benzoyl peroxide and mixtures thereof. The most preferred is salicylic acid. Pharmaceutical active ingredients useful in the compositions of the present invention include nonsteroidal anti-inflammatory drugs (NSAIDs). The NSAIDs can be selected from the following categories: propionic acid derivatives; acetic acid derivatives; phenamic acid derivatives; biphenyl carboxylic acid derivatives; and oxicam. All of these NSAIDs are described fully in the US patent. 4,985,459 for Sunshine et al, issued January 15, 1991, incorporated herein by reference. Most preferred are the propionic NSAIDs including but not limited to aspirin, acetaminophen, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, thioxaprofen, suprofen, alminoprofen, thiaprofenic acid , fluprofen and blucoxic acid. Steroidal antiinflammatory drugs including hydrocortisone and the like are also useful. Pharmaceutical active ingredients useful in the compositions of the present invention include antipruritic drugs. Preferred antipruritic drugs for inclusion herein include the pharmaceutically acceptable salts of metdilizine and trimeprazine. Pharmaceutical active ingredients useful in the compositions of the present invention include anesthetic drugs. Preferred anesthetic drugs for inclusion herein include pharmaceutically acceptable salts of lidocaine, bupivicaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, diclionine, hexylcaine, procaine, cocaine, ketamine, pramoxin and phenol. The active pharmaceutical ingredients useful in the compositions of the present invention include antimicrobial drugs (antibacterial, antifungal, antiprotozoal and antiviral). Preferred antimicrobial drugs for inclusion herein include pharmaceutically acceptable salts of beta-lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, triclosan, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracycline, clindamycin, ethambutol, metronidazole, pentamidine, gentamicin, kanamycin, lineomycin, methacycline, methenamine, minocycline, neomycin, netilmicin, paraomonicin, streptomycin, tobramycin, miconazole and amanfadine. Preferred antimicrobial drugs to be included herein include tetracycline hydrochloride, erythromycin estolate, erythromycin stearate (salt), amikacin sulfate, doxycycline clohydrate, capromycin sulfate, chlorhexidine gluconate, chlorhexidine hydrochloride, chlorhexidine hydrochloride, hydrochloride of chlortetracycline, oxytetracycline hydrochloride, clindamycin hydrochloride, ethambutol hydrochloride, metronidazole hydrochloride, pentamidine hydrochloride, gentamicin sulfate, kanamycin sulfate, lineomycin hydrochloride, metacycline hydrochloride, methanamine hippurate, methenamine mandelate, minocycline hydrochloride , neomycin sulfate, methylmycin sulfate, paromomycin sulfate, streptomycin sulfate, tobramycin sulfate, miconazole hydrochloride, amanfadine hydrochloride, amanfadine sulfate, triclosan, octopirox, parachlorometha xylenol, nystatin, tolnaftate and clotrimazole. Also useful herein are sun blocking agents. A wide variety of sunblocks is described in the patent E.U.A. 5,087,445, for Haffey et al, issued February 11, 1992; patent E.U.A. 5,073,372, for Turner et al, issued December 17, 1991; patent E.U.A. 5,073,371, for Turner et al issued on December 17, 1991; and Segarin, et al, in Chapter VIII, page 189 et seq, of Cosmetics Science and Technology, of which all are incorporated herein by reference in their entirety. Preferred among those sunscreens which are useful in the compositions of the present invention are those which are selected from the group consisting of 2-ethylhexyl p-methoxycinnamate, 2-ethylhexyl N, N-dimethyl-p-aminobenzoate, p-aminobenzoic acid, 2-phenylbenzimidazole-5-sulfonic acid, octocrylene, oxybenzone, homomenthyl salicylate, octyl salicylate, 4,4'-methoxy-t-butyldibenzoylmethane, 4-isopropyl dibenzoylmethane, 3-benzylidene camphor, 3- (4-methylbenzylidene) camphor, titanium dioxide, zinc oxide, silica, iron oxide and mixtures thereof. Even other useful sunblocks are those described in the US patent. 4,937,370, for Sabatelli, issued on June 26, 1990; and the patent E.U.A. 4,999,186, for Sabatelli et al, issued March 12, 1991; These two references are incorporated herein by reference in their entirety. The sunscreen agents described in these documents have, in a single molecule, two distinct chromophoric portions that exhibit different absorption to ultraviolet radiation. One of the chromophore portions absorbs predominantly in the UVB radiation range and the other obstructs strongly in the UVA radiation range. These sunscreen agents provide greater efficacy, broad UV absorption, less penetration of the skin and long-lasting efficacy compared to conventional sunscreens. Especially preferred examples of these sunblockers include those selected from the group consisting of 4-N, N- (2-ethylhexyl) methylaminobenzoic acid ester of 2,4-dihydroxybenzophenone, 4-N, N- ( 2-ethylhexyl) methylaminobenzoic acid with 4-hydroxybenzoylmethane, 4-N, N- (2-ethylhexyl) methylaminobenzoic acid ester of 2-hydroxy-4- (2-hydroxyethoxy) benzophenone, 4-N, N- (2 -ethylhexyl) -methylaminobenzoic acid of 4- (2-hydroxyethoxy) dibenzoylmethane, and mixtures thereof. Generally, the compositions may comprise from 0.5% to about 20% of the sunscreens useful herein. The exact amounts will vary depending on the chosen sunblock and the desired sun protection factor (SPF). SPF is a commonly used photoprotection measure of a sunscreen against erythema. See Federal Reqister, Vol. 43, No. 166, pp. 38206-38269, August 25, 1978, which is incorporated herein by reference in its entirety.
Sunless tanning agents including dihydroxyacetone, glyceraldehyde, and their derivatives and the like are also useful in the compositions of the present invention. These sunless tanning agents can also be used in combination with sunscreen agents. Other useful active ingredients include skin brighteners (or brighteners) including, but not limited to, hydroquinone, ascorbic acid, kojic acid and sodium metabisulfite.
Moisturizers and Moisturizers The compositions of the present invention may also contain one or more additional humectant or moisturizing materials other than those described in the present invention. A variety of these materials may be used and each may be present at a level from 0.1% to 20%, preferably from 1% to 10% and more preferably from 2% to about 5% by weight of the composition. These materials include guanidine; glycolic acid and the glycolate salts (for example ammonium and quaternary alkyl ammonium); lactic acid and lactates (for example ammonium and alkyl quaternary ammonium); aloe vera in any of its various forms (for example aloe vera gel); polyhydroxy alcohols such as sorbitol, glycerol, hexanetriol, propylene glycol, butylene glycol, hexylene glycol and the like; sugars and starches, sugar and starch derivatives (for example alkoxylated glucose); hyaluronic acid; lactamido methanolamine; acetamidomonoethanolamine; and mix them.
Emulsifiers The compositions herein may contain various emulsifiers. These emulsifiers are useful for emulsifying the various vehicle components of the compositions of the present invention. Suitable emulsifiers may include any of a wide variety of nonionic, cationic and zwitterionic emulsifiers described in the prior art patents and other references. See McCutcheon's, Detergents and Emulsifiers. American edition (1986), published by Allured Publishing Corporation; patent E.U.A. No. 5,011, 681 for Ciotti et al., issued April 30, 1991; patent E.U.A. No. 4,421, 769 for Dixon et al., issued December 20, 1983; and patent E.U.A. No. 3,755,560 for Dickert et al., issued August 28, 1973; These four references are incorporated herein by reference in their entirety. Suitable types of emulsifiers include glycerin esters, propylene glycol esters, polyethylene glycol esters of fatty acids, polypropylene glycol esters of fatty acids (excluding the propylene glycol esters of CrC6 carboxylic acid useful as the solid oil herein), esters of sorbitol, esters of sorbitan anhydride, carboxylic acid copolymers, glucose esters and ethers, ethoxylated ethers, ethoxylated alcohols, alkyl phosphates, fatty polyoxyethylene ether phosphate, fatty acid amides, acyl lactylates, soaps and mixtures thereof. Suitable emulsifiers may include, but are not limited to, polyethylene glycol 20 (polysorbate 20) sorbitanmonolaurate, polyethylene glycol 5 sterol, Steareth-20, Ceteareth-20, PPG-2 methyl glucose ether distearate, Ceteth-10, Polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, Polysorbate 60, glyceryl stearate, PEG-100 stearate and mixtures thereof. The emulsifiers can be used individually or as a mixture of 2 or more and can be included in concentrations ranging from 0.1% to approximately 10%, preferably from near
1% to about 7%, and more preferred from 1% to about 5% by weight of the composition.
Thickeners based on carboxylic acid copolymer Another useful component in the compositions of the present invention is a thickener based on carboxylic acid copolymer. These cross-linked polymers contain one or more monomers that are obtained from acrylic acid, substituted acrylic acids and salts and esters of these acrylic acids and substituted acrylic acids, wherein the cross-linking agent contains 2 or more carbon-carbon double bonds and is obtained from a polyhydric alcohol. The preferred polymers to be used herein are of two general types. The first type of polymer is a crosslinked homopolymer of an acrylic acid monomer or derivative thereof (for example, wherein the acrylic acid has substituents at the carbon 2 and 3 positions which are independently selected from the group consisting of C1 alkyl. -4, -CN -COOH, and mixtures thereof). The second type of the polymer is a crosslinked copolymer having a first monomer that is selected from the group consisting of acrylic acid monomer or derivative thereof (as just described in the previous sentence), an acrylate ester monomer of short chain alcohol (i.e. a C-) alcohol OR derivative thereof (e.g., wherein the acrylic acid portion of the ester has substituents at the carbon 2 and 3 positions independently selected from the group consisting of C-alkyl -4, -CN, -COOH, and mixtures thereof), and mixtures thereof; and a second monomer which is a long-chain alcohol acrylate ester monomer (ie Cs-4o) or derivative thereof (eg, wherein the acrylic acid portion of the ester has substituents at the carbon 2 and 3 independently selected from the group consisting of C? -4 alkyl, -CN, -COOH, and mixtures thereof). The combinations of these two types of polymers are also useful in the present invention. In the first type of crosslinked homopolymers the monomers are preferably selected from the group consisting of acrylic acid, methacrylic acid, ethacrylic acid and mixtures thereof, with acrylic acid being most preferred. In the second type of crosslinked copolymers the acrylic acid monomer or derivative thereof is preferably selected from the group consisting of acrylic acid, methacrylic acid, ethacrylic acid and mixtures thereof, with acrylic acid, methacrylic acid being most preferred. and mixtures thereof. The short chain alcohol acrylate ester monomer or derivative thereof is preferably selected from the group consisting of C? -4 alcohol acrylate esters, C? -4 alcohol alcohol methacrylate esters, ethacrylate esters of C? -4 alcohol alcohol, C.sub.4 alcohol and mixtures thereof, the most preferred being alcohol C-4 alcohol acrylate esters, C- alcohol methacrylate esters and mixtures thereof. The long chain alcohol acrylate ester monomer is selected from the group consisting of Cß-40 alkyl acrylate esters, with C este-3o alkyl acrylate esters being the most preferred * The crosslinking agent in both types of these polymers is a polyalkenyl polyester of a polyhydric alcohol containing more than one alkenyl ether group per molecule, wherein the parent polyhydric alcohol contains at least 3 carbon atoms and at least 3 hydroxyl groups. Preferred crosslinkers are those that are selected from the group consisting of allylethers of sucrose and allyletters of pentaerythritol, and mixtures thereof. These useful polymers of the present invention are described more fully in the U.S.A. No. 5,087,445, for Heffey et al., issued February 11, 1992; patent E.U.A. No. 4,509,049, for Huang et al., issued April 5, 1985; patent E.U.A. No. 2,798,053, for Brown, issued July 2, 1957; which are incorporated for reference herein. See also CTFA International Cosmetic Ingredient Dictionarv, fourth edition 1991, pages 12 and 80; which is also incorporated for reference herein. Examples of commercially available homopolymers of the first type useful herein include carbomers, which are homopolymers of acrylic acid crosslinked with allylic ethers of sucrose or pentaerythritol. Carbomers can be obtained as the Carbopol® 900 series from B-F. Goodrich. Examples of commercially available second type copolymers useful herein include copolymers of C10-30 alkyl acrylate with one or more acrylic acid monomers, methacrylic acid or one of its short chain d-alcohol ethers, wherein the cross-linking agent is an allyl ether of sucrose or of pentaerythritol. These copolymers are known as cross-linked acrylate / alkyl acrylate polymers of C 0-3 o and are commercially available as Carbopol® 1342, TR-1, and Pemulen TR-2, from B-F. Goodrich. In other words, examples of carboxylic acid polymer-based thickeners useful herein are those that are selected from the group consisting of carbomers, crosslinked polymers of acrylates / C- or C 30 alkyl acrylate and mixtures thereof . The compositions of the present invention may comprise from 0.025% to about 1%, preferably from 0.05% to about 0.75% and more preferably from 0.10% to about 0.50% by weight of the carboxylic acid polymer based thickeners.
Other additional components The compositions of the present invention may comprise a wide variety of other additional components. The CTFA Cosmetic Ingredient Handbook, second edition, 1992, which is incorporated herein by reference in its entirety, discloses a wide variety of non-limiting cosmetic and pharmaceutical ingredients commonly used in hair and skin care industries, which are suitable for use in the compositions of the present invention. Non-limiting examples of functional classes of ingredients are described on pages 537 of this reference. Examples of these functional classes include: absorbers, abrasives, anti-acne agents, anti-tanning agents, antifoaming agents, antimicrobial agents, antioxidants, binders, biological additives, pH regulating agents, bodily agents, chelating agents, chemical additives, dyes, cosmetic astringents , cosmetic biocides, denaturants, drug-based astringents, film formers, fragrance components, opacifying agents, pH adjusters, plasticizers, preservatives, propellants, reducing agents, additional skin conditioning agents, suspending agents (non-surfactants) , ultraviolet light absorbers and viscosity increasing agents (aqueous and non-aqueous). Examples of other functional classes of useful materials of the present invention are those known to the person skilled in the art and include solubilizing agents, sequestering agents and the like.
Non-limiting examples of these additional components cited in CTFA Cosmetic Inqredient Handbook. as well as other materials useful herein, include the following: vitamins and derivatives thereof [e.g. vitamin C, vitamin A (ie retinoic acid), retinol, retinoids and the like]; antioxidants; polyethylene glycols; polymers to assist the film formation and substantive properties of the composition (such as a copolymer of eicosene and vinyl pyrrolidone, an example of which can be obtained from GAF Chemical Corporation as Ganex® V-200); preservatives to maintain the antimicrobial integrity of the compositions; antioxidants; chelators and sequestrants; crosslinked and non-crosslinked cationic and nonionic polyacrylamides [eg Saleare SC92 which has the CTFA designation polyquatemium 32 (and) mineral oil, and Saleare SC95 which has the CTFA designation polyquaternium 37 (and) mineral oil (y) PPG-1 trideceth -6, and the non-ionic Seppi-Gel polyacrylamides available from Seppic Corp.]; and aesthetic components such as fragrances, pigments, dyes, essential oils, skin sensitizers, astringents, skin comfort agents, skin healing agents and the like, non-limiting examples of these aesthetic components include clove oil, menthol, camphor , eucalyptus oil, eugenol, methyl lactate, witch hazel distillate, bisabolol, dipotassium glycyrrhizinate, and the like.
Method of use The compositions of the present invention are used in conventional ways to provide cosmetic or pharmaceutical benefits appropriate to the product such as sun protection, anti-acne benefits, anti-wrinkle and anti-aging benefits of the skin, artificial tanning, analgesic benefits, conditioning benefits of skin, facial moisturization, lip protection, cleansing benefits of the skin, grooming aids and the like. Such methods of use depend on the type of composition used but generally involve the topical application of an effective amount of the product to the hair or skin. By "effective amount" is meant an amount sufficient to provide the desired benefit. The typical amounts of the compositions of the present invention that are applied to the hair or skin will vary depending on the type of composition and the desired benefit, however, typical ranges generally range from 1 gram to 25 grams, with approximately 2 grams being typical.
EXAMPLES
The following examples further describe and demonstrate the embodiments within the scope of the present invention. The examples are given solely for the purpose of illustration and should not be construed as limitations of the present invention, since many variations thereof are possible without departing from the scope and scope of the invention.
The ingredients are identified by their chemical name or CTFA name.
EXAMPLE 1
A topical composition is prepared in the form of an emollient cleanser by combining the following ingredients using conventional mixing techniques. This composition uses a mixture of a polyol polyester of liquid fatty acid (liquid sucrose polyester) and a solid oil to provide the emolliency and aesthetic benefits without leaving the skin feeling heavy, sticky or oily.
Ingredients Percent in Phase A Disodium EDTA 0.100 Glycerin 4,000 Methylparaben 0.200 Crosslinked Polymer of 0.150 Acrylates / Ala-Cryl Acrylate 1 Carbomer 9542 0.250 Water CBP 100 Phase B Stearic Acid 0.110 Stearic Alcohol 0.875 Cetyl Alcohol 0.875 Propylparaben 0.150 Steareth-2 0.250 Steareth -21 0.500 Liquid sucrose polyester3 2.780 Ethylene glycol distearate 0.220 Phase C Sodium hydroxide4 0.130 Phase D Diisopropyl sebacate 1,500 Isohexadecane 5,000 Phase E Phenoxyethanol 0.500 Fragrance 0.150 Phase F Glucosamide 0.960 1Available as Pemulen®TR-1 in BF Goodrich Corporation. 2Dis available as Carbomer®954 in B.F. Goodrich Corporation. 3 The liquid sucrose polyester is a mixture of hexa-, hepta-, and sucrose octaesters, predominantly the octaester esterified with mixed soybean oil fatty acids. 4Solution accuses 50%.
In an appropriate vessel, the ingredients of phase A are mixed at room temperature to form a dispersion and heated with stirring between 70-80 ° C. In a separate container, the ingredients of phase B are heated with stirring between 70-80 ° C. Then phase B is added to A with mixing to form the emulsion. Next, phase C is added to neutralize the composition. The ingredients of phase D are added with mixing, stirring to cool to 45-50 ° C. The ingredients of phase E are then added with stirring, followed by cooling to 40 ° C. Phase F is heated with stirring at 40 ° C and the emulsion is added, which is cooled to room temperature.
EXAMPLE 2
A topical composition was prepared in the form of a shower product by combining the following ingredients using conventional mixing techniques. This composition uses a mixture of a polyol polyester fatty acid polyester (liquid sucrose polyester) and a solid oil to provide the emolliency and aesthetic benefits without leaving the skin feeling heavy, sticky or greasy.
Ingredients Weight percent Alkyl (C12.14) ether glycerol sodium sulfonate 12.0 Laureth-3 ammonium sulfonate 3.00 Myristic acid 1.00 Myristic alcohol 1.00 Cocamidopropylbetaine 3.00 Liquid sucrose polyester1 15.3 Petrolatum 2.00 tetrasodium EDTA 0.13 Glycerin 6.24 Perfume 0.80 Poliquat-10 (JR -30M) 0.30 Slider 0.20 Water CBP 100 1EI Liquid sucrose polyester is a mixture of hexa-, hepta-, and octa-esters of sucrose, predominantly the octaester esterified with mixed fatty acids of soybean oil.
In a suitable container, add the Polyquat-10 to distilled water and let it mix until it is completely hydrated. The surfactants, and the water soluble ingredients, are added and the mixture is heated with stirring at 70-80 ° C. In a separate vessel, the solid sucrose polyester is combined with the liquid oils, heated with stirring until uniform and then added to the heated mixture at 70-80 ° C. The mixture is allowed to cool to 25-35 ° C while continuing to stir. The slider and the perfume ingredients are then added with stirring and the mixture is cooled to room temperature.
EXAMPLE 3
A topical composition was prepared in the form of a shower product by combining the following ingredients using conventional mixing techniques. This composition uses a mixture of a polyol polyester fatty acid polyester (liquid sucrose polyester) and a solid oil to provide the emolliency and aesthetic benefits without leaving the skin feeling heavy, sticky or greasy.
Ingredients Percent by weight Ammonium lauryl sulfate 3.15 Laureth-3 Ammonium sulfate 9.45 Lauroanfoacetate Na 5.40 Polyquaternium-10 0.30 Polyester liquid sucrose 15.3 Behenyl behenate 2.00 Tetrasodium EDTA 0.13 Glycerin 3.00 Perfume 0.80 Citric acid 0.76 Lauryl alcohol 2.00 Water CBP 100 1EI polyester Sucrose liquid is a mixture of hexa-, hepta-, and octa-esters of sucrose, predominantly the octaester esterified with fatty acids of mixed soybean oil.
In an appropriate container, polyquaternium-10 is added to
distilled water and let it mix until it is completely hydrated. The surfactant, and water soluble ingredients, are added and the
The mixture is heated with stirring at 70-80 ° C. In a separate container, the
Solid sucrose polyester combines with liquid oils, and alcohol
lauryl, heated with mixing until uniform and then
add to the heated mixture at 70-80 ° C. The mixture is allowed to cool to 25-35 ° C
while it continues to stir. The slider and perfume ingredients
they are then added with stirring, and the mixture is cooled to room temperature
ambient.
EXAMPLE 4
A topical composition in the form of a humectant was prepared by combining the following ingredients using conventional mixing techniques. This composition uses a mixture of a polyol polyester fatty acid polyester (liquid sucrose polyester) and a solid oil to provide the emolliency and aesthetic benefits without leaving the skin feeling heavy, sticky or greasy.
Ingredients Percent by weight Cetyl alcohol 1.80 Stearic acid 0.25 Stearyl alcohol 1.20 PEG 100 stearate 0.25 Mineral oil 2.00 Petrolatum 1.50 Isopropyl palmitate 1.00 Cetyl ricinoleate 1.00 Liquid sucrose polyester1 4.00 Dimethicone 3502 0.50 Propyl paraben 0.10 Arlatone (RTM) 21213 1.00 Glycerin 9.00 Urea 2.00 Octyl methoxycinnamate 2.00 Phenoxyethanol 0.25 Carbomer 13824 0.05 Carbomer 9545 0.35 Tetrasodium EDTA 0.10 Titanium dioxide 0.15 Methyl paraben 0.20 NaOH 0.22 Dimethicone Q-214036 1.00 Ethylene glycol distearate 1.00 Water CBP 100 Liquid sucrose is a mixture of hexa-, hepta -, and octa esters of sucrose, predominantly the octaester esterified with fatty acids of mixed soybean oil.
2 Dow Coming®200 Fluid (350 centistoke) from Dow Corning. 395% by weight of sorbitan stearate and 5% of sucrose cocoate. 4Carbopol® 1382 from B.F. Goodrich. 5Carbopol® 954 from B.F. Goodrich. 6 Dow Corning® Q-2 1403 from Dow Corning which is a blend of 85% by weight of dimethicone and 15% by weight of dimethicone.
A first premix of liquid sucrose polyester, Arlatone 2121 and other water-soluble ingredients is prepared by mixing them in water and heating them. A second premix of the oil phase ingredients other than the silicones is prepared by mixing and heating and added to the aqueous premix. The resulting mixture is cooled. The silicones are then added to the resulting oil-in-water emulsion and the mixture is cooled before adding the minor ingredients.
Claims (10)
1. A composition comprising a combination of polyol polyester fatty acid polyester having a melting point between -30 ° C and 30 ° C, and a solid oil other than polyol fatty acid solid polyester having a melting point above 30 ° C to 250 ° C, characterized in that said liquid polyol fatty acid polyester has a polyol portion and at least a fatty acid portion, the polyol portion having at least 4 free hydroxyl groups wherein at least 60% of these free hydroxyl groups are esterified with one or more fatty acid portions having from 8 to 22 carbon atoms.
2. A topical composition comprising: (a) from 0.1% to 99% by weight of a combination of a polyol polyester fatty acid polyester having a melting point between -30 ° C and 30 ° C, and a solid oil different from a polyol fatty acid solid polyester having a melting point of between 30 ° C and 250 ° C, characterized in that said polyol fatty acid polyester has a polyol portion and at least a fatty acid portion, having the polyol portion at least 4 free hydroxyl groups wherein at least 60% of these free hydroxyl groups are esterified with one or more fatty acid portions having from 8 to 22 carbon atoms; (b) from 0.1% to 99.9% by weight of a topical vehicle.
3. The composition according to claim 2, further characterized in that the topical vehicle is an oil-in-water emulsion.
4. The composition according to claim 2, further characterized in that the topical vehicle is an anhydrous liquid solvent. The composition according to claims 2, 3 or 4 further characterized in that the composition is in the form of a hand lotion, a body lotion, a skin conditioning cream, a skin protector, a sunscreen sunscreen, a fading cream, an anti-acne composition, a skin renewal product, a non-foaming cleansing lotion, a moisturizer, a facial moisturizer, makeup, foundation, lipstick, lip balm, hand cleaner, facial cleanser, cleanser body, product for shower, shampoo and mixtures thereof. The composition of any of the preceding claims, further characterized in that the polyol portion is selected from the group consisting of erythritol, xylitol, sorbitol, glucose, sucrose and mixtures thereof. The composition according to any of the preceding claims, further characterized in that the polyol portion is sucrose. The composition according to any of the preceding claims, further characterized in that the solid oil is selected from the group consisting of petrolatum, highly branched hydrocarbons, fatty alcohols, fatty acid esters, vegetable oils, hydrogenated vegetable oils, propylene glycols, alpha -hydroxy fatty acids, fatty acids having from 10 to 40 carbon atoms, alkylamides of dibasic carboxylic acids, alkylamides of tribasic carboxylic acids, n-acylamino acid derivatives and mixtures thereof. A method for treating human hair or skin comprising topically applying to a human in need of treatment a safe and effective amount of a composition according to claim 1. 10. A treatment method for human hair or skin comprising the topically applying to a human in need of treatment a safe and effective amount of a composition according to claim 2. SUMMARY OF THE INVENTION Suitable compositions for topical application to hair or human skin are described, which comprise a combination of a polyol polyester fatty acid polyester having a melting point between -30 ° C and 30 ° C, and a solid oil different from that of polyester polyol fatty acid solid having a melting point above 30 ° C to 250 ° C, wherein said polyolef liquid polyol fatty acid has a polyol portion and at least a fatty acid portion, the polyol portion having the at least 4 free hydroxyl groups wherein at least 60% of these free hydroxyl groups are esterified with one or more fatty acid portions having from 8 to 22 carbon atom; the composition preferably also comprises a topical vehicle for the combination of polyol fatty acid polyester and solid oil; the composition provides effective emolliency and aesthetic benefits. P99 / 1530F JT / abg * slPeos * jtc.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08862344 | 1997-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99010840A true MXPA99010840A (en) | 2000-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0794764B1 (en) | Topical skin care compositions containing thickened polyol carboxylic acid esters as skin conditioning agents | |
AU706920B2 (en) | Compositions for topical delivery of active ingredients | |
EP1032355A1 (en) | Compositions containing combinations of liquid polyol fatty acid polyesters and a liquid oil | |
KR100276457B1 (en) | Cleansing emulsions | |
KR19990035891A (en) | Compositions for topical application with improved skin feel | |
US20010055599A1 (en) | Compositions containing select liquid polyol fatty acid polyesters | |
MXPA97003895A (en) | Topical compositions for care of the skin containing esters of carboxylic acid of poliol thickened as agents of conditioning of the p | |
US20020039561A1 (en) | Topical skin care compositions containing thickened polyol carboxylic acid esters as skin conditioning agents | |
WO1998052531A1 (en) | Compositions containing select solid polyol fatty acid polyesters | |
WO1999024010A1 (en) | Compositions containing combinations of solid polyol fatty acid polyesters and a solid oil | |
EP0794765B1 (en) | Topical skin care compositions containing nonocclusive liquid polyol carboxylic acid esters as skin conditioning agents | |
MXPA99010840A (en) | Compositions containing select liquid polyol fatty acid polyesters | |
MXPA99010832A (en) | Compositions containing select solid polyol fatty acid polyesters | |
MXPA00004530A (en) | Compositions containing combinations of liquid polyol fatty acid polyesters and a liquid oil | |
MXPA97003896A (en) | Topical compositions for care of the skin containing esters of carboxylic acid of non-oclusive liquid polyol as agents of conditioning of the p | |
CZ410299A3 (en) | Mixtures containing combination of solid ester of polyhydroxylic fatty acid and liquid oil used for treating human hair and skin | |
CZ410399A3 (en) | Preparations containing selected liquid polyhydroxyl polyesters of fatty acids |